Patents by Inventor Benoit Destenaves

Benoit Destenaves has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-ALPHA-V INTEGRIN ANTIBODY FOR THE TREATMENT OF PROSTATE CANCER
    Publication number: 20190263913
    Abstract: The invention is directed to the treatment of prostate cancer by means of antibodies. Above all, the invention relates to the administration of an anti-alpha-v integrin (receptor) antibody to patients suffering from prostate cancer, especially castration-resistant prostate cancer (CRPC), optionally accompanied by lymph node and bone tissue metastases (mCRPC). In particular, the invention relates to the therapy of said patients by means of the anti-angiogenic antibody DI17E6 and structural mutants thereof.
    Type: Application
    Filed: January 25, 2019
    Publication date: August 29, 2019
    Inventors: Axel Hoffmann, Heinrich Lannert, Klaus Brischwein, Frederic Christian Pipp, Juergen Reindl, Karin Groll, Michael Zuehlsdorf, Otmar Pfaff, Sabine Raab, Ulrike Dau, Benoit Destenaves
  • ANTI-ALPHA-V INTEGRIN ANTIBODY FOR THE TREATMENT OF PROSTATE CANCER
    Publication number: 20170218070
    Abstract: The invention is directed to the treatment of prostate cancer by means of antibodies. Above all, the invention relates to the administration of an anti-alpha-v integrin (receptor) antibody to patients suffering from prostate cancer, especially castration-resistant prostate cancer (CRPC), optionally accompanied by lymph node and bone tissue metastases (mCRPC). In particular, the invention relates to the therapy of said patients by means of the anti-angiogenic antibody DI17E6 and structural mutants thereof.
    Type: Application
    Filed: January 9, 2017
    Publication date: August 3, 2017
    Applicant: Merck Patent GmbH
    Inventors: Axel Hoffmann, Heinrich Lannert, Klaus Brischwein, Frederic Christian Pipp, Juergen Reindl, Karin Groll, Michael Zuehlsdorf, Otmar Pfaff, Sabine Raab, Ulrike Dau, Benoit Destenaves
  • Anti-alpha-V integrin antibody for the treatment of prostate cancer
    Patent number: 9555110
    Abstract: The invention is directed to the treatment of prostate cancer by means of antibodies. Above all, the invention relates to the administration of an anti-alpha-v integrin (receptor) antibody to patients suffering from prostate cancer, especially castration-resistant prostate cancer (CRPC), optionally accompanied by lymph node and bone tissue metastases (mCRPC). In particular, the invention relates to the therapy of said patients by means of the anti-angiogenic antibody DI17E6 and structural mutants thereof.
    Type: Grant
    Filed: February 7, 2012
    Date of Patent: January 31, 2017
    Assignee: Merck Patent GmbH
    Inventors: Axel Hoffmann, Heinrich Lannert, Klaus Brischwein, Frederic Christian Pipp, Juergen Reindl, Karin Groll, Michael Zuehlsdorf, Otmar Pfaff, Sabine Raab, Ulrike Dau, Benoit Destenaves
  • Genomic markers for prediction of long-term response to 2 years of growth hormone (GH) therapy
    Patent number: 9206480
    Abstract: The present invention relates to the use of genetic markers to identify the response to growth hormone treatment in Growth Hormone Deficiency (GHD) or Turner Syndrome (TS) patients as well as a method of treating GHD or TS patients and kits for genotyping.
    Type: Grant
    Filed: May 10, 2012
    Date of Patent: December 8, 2015
    Assignee: ARES TRADING S.A.
    Inventors: Pascal Croteau, Benoit Destenaves, Clement Olivier, John Raelson
  • ANTI-ALPHA-V INTEGRIN ANTIBODY FOR THE TREATMENT OF PROSTATE CANCER
    Publication number: 20140086908
    Abstract: The invention is directed to the treatment of prostate cancer by means of antibodies. Above all, the invention relates to the administration of an anti-alpha-v integrin (receptor) antibody to patients suffering from prostate cancer, especially castration-resistant prostate cancer (CRPC), optionally accompanied by lymph node and bone tissue metastases (mCRPC). In particular, the invention relates to the therapy of said patients by means of the anti-angiogenic antibody DI17E6 and structural mutants thereof.
    Type: Application
    Filed: February 7, 2012
    Publication date: March 27, 2014
    Applicant: Merck Patent GmbH
    Inventors: Axel Hoffmann, Heinrich Lannert, Klaus Brischwein, Frederic Christian Pipp, Juergen Reindl, Karib Groll, Michael Zuehlsdorf, Otmar Pfaff, Sabine Raab, Ulrike Dau, Benoit Destenaves
  • GENOMIC MARKERS FOR PREDICTION OF LONG-TERM RESPONSE TO 2 YEARS OF GROWTH HORMONE (GH) THERAPY
    Publication number: 20140088012
    Abstract: The present invention relates to the use of genetic markers to identify the response to growth hormone treatment in Growth Hormone Deficiency (GHD) or Turner Syndrome (TS) patients as well as a method of treating GHD or TS patients and kits for genotyping.
    Type: Application
    Filed: May 10, 2012
    Publication date: March 27, 2014
    Applicant: ARES TRADING S.A.
    Inventors: Pascal Croteau, Benoit Destenaves, Clement Olivier, John Raelson
  • KCNQ2-15 potassium channel
    Patent number: 7442519
    Abstract: The invention encompasses polypeptides and polynucleotides of three novel bipolar disorder-associated potassium channel polypeptides, KCNQ2-15bx, KCNQ2-15by and KCNQ2-15bz. The invention further relates to the use of potassium channels comprising KCNQ2 subunits for screening for modulators thereof, the use of these modulators for treating mental disorders such as bipolar disorder, schizophrenia and depression, and drugs comprising these modulators. The invention also discloses biallelic markers located in the KCNQ2 gene and their use for diagnosing mental disorders.
    Type: Grant
    Filed: June 20, 2003
    Date of Patent: October 28, 2008
    Assignee: Serono Genetics Institute, S.A.
    Inventors: Laurent Cavarec, Ilya Chumakov, Benoit Destenaves, Catherine Gonthier, Isabelle Elias
  • Novel kcnq polypeptides, modulators thereof, and their uses in the treatment of mental disorders
    Publication number: 20060099210
    Abstract: The invention encompasses polypeptides and polynucleotides of three novel bipolar disorder-associated potassium channel polypeptides, KCNQ2-15bx, KCNQ2-15by and KCNQ2-15bz. The invention further relates to the use of potassium channels comprising KCNQ2 subunits for screening for modulators thereof, the use of these modulators for treating mental disorders such as bipolar disorder, schizophrenia and depression, and drugs comprising these modulators. The invention also discloses biallelic markers located in the KCNQ2 gene and their use for diagnosing mental disorders.
    Type: Application
    Filed: June 20, 2003
    Publication date: May 11, 2006
    Applicant: Serono Genetics Institute S. A.
    Inventors: Laurent Cavarec, Ilya Chumakov, Benoit Destenaves, Catherine Gonthier, Isabelle Elias